HIV SUSTIVA

HIV SUSTIVA

Sustiva is anti-HIV therapy. It is in the category of HIV medicines, called non-nucleoside reverse transcriptase inhibitors (NNRTIs). Sustiva prevents HIV from entering healthy nucleus of T-cells. This prevents the cells from producing new virus, and reduces the virus in the body.
Sustiva was approved by the United States Food and medicines for the treatment of HIV in 1998. He was originally trained DuPont Pharmaceuticals, and is currently manufactured at Bristol-Myers Squibb for sale in the United States. In Europe and in many other parts of the world, Sustiva is a brand: Stocrin. Stocrin is manufactured by the company Merck Sharp and Dohme. Stocrin and Sustiva, the same drugs.
Sustiva should be used in combination with other drugs to treat HIV infection. This usually in combination with two nucleoside reverse transcriptase inhibitors (NRTIs).
Atripla, a combination pill containing Sustiva and NRTIs Viread (tenofovir), and Emtriva (emtricitabine), was approved for use in the United States in July 2006. Sustiva more can be purchased separately for use in combination with anti-HIV drugs, in addition to Viread, Emtriva, or Truvada (tenofovir and emtricitabine combined).
HIV SUSTIVA
What is known about Sustiva?
In Sustiva dose for adults is one 600mg tablet to take once a day.
Because Sustiva may cause sleepiness, dizziness, and the problem of concentration, it's probably better to take it at bedtime.
He recommended that Sustiva be taken on an empty stomach.
Children who are able to swallow the capsule can take Sustiva. Capsules containing smaller doses Sustiva there. Your child will determine the right dose of the doctor, depending on the child's age and body weight. To learn more about Sustiva dosage for children here. For children who can not swallow capsules, liquid formulation Sustiva is being developed by the manufacturer. Currently available through expanded access "program. If you care for a child requiring Sustiva, which could not swallow capsules, a health may enroll the child in an expanded access program by calling this number: (877) 372-7097.
For HIV-infected adults who start on HIV drug therapy for the first time, Sustiva is listed as "preferred" NNRTI option that the United States Department of Health and Human Services (DHHS), in its treatment guidelines. In NNRTI Viramune (nevirapine) is registered as an "alternative" version. To learn more about these recommendations and options, click here.
In DHHS recommends Sustiva will not be used during the first trimester (first three months) of pregnancy. HIV-positive women who are trying to get pregnant or not correctly and consistently using birth control during sex, should not use Sustiva.
If the viral load becomes detectable when taking the drug regime, which contains Sustiva, your doctor may order a drug-resistance test to see what your virus drugs become less sensitive j.
All evidence to date NNRTIs suffer from the cross-resistance. This means that if you have already tried, and is not a drug treatment in the past that contained either Viramune (nevirapine), or Rescriptor (delavirdine), a virus could be resistant to Sustiva. Similarly, if you are going to combat HIV drug treatment, which contains Sustiva and your virus becomes resistant to the drug, a virus is likely to be resistant to other NNRTIs. That is why it is very important that the use of drug resistance testing to determine which drugs your virus does not respond in the event that you experience in your rise in viral load when taking anti-HIV drug treatment. Fortunately, the new NNRTIs that are active against HIV strains resistant to current NNRTIs are currently being developed.
If you decide not to accept the drug regime, which contains Sustiva and not immediately switch to a different regime of drugs, careful planning is needed. It may take two to three weeks to Sustiva be completely eliminated from the body, while it only takes other anti-HIV drugs in a few days will be completely eliminated. If you stop taking the medication regime, which contains Sustiva, for instance, Sustiva and Combivir and not immediately switch to a different regime, it would be as Sustiva without taking any other medication, which can quickly lead to drug resistance. In turn, if you plan to stop drug treatment, which contains Sustiva, and they do not plan to immediately transition to the new regime, it is best to stop Sustiva first, a few days before to stop other anti-HIV drugs (for example, in the Combivir) . You have to plan it, to your health to stop your drug treatment.